A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder
- PMID: 35778967
- PMCID: PMC9796364
- DOI: 10.1111/acps.13471
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder
Abstract
Objectives: Rapid cycling is a common and disabling phenomenon in individuals with bipolar disorders. In the absence of a recent literature examination, this systematic review and meta-analysis aimed to synthesise the evidence of efficacy, acceptability and tolerability of treatments for individuals with rapid cycling bipolar disorder (RCBD).
Method: A systematic search was conducted to identify randomised controlled trials assigning participants with RCBD to pharmacological and/or non-pharmacological interventions. Study inclusion and data extraction were undertaken by two reviewers independently. The primary outcome was continuous within-subject RCBD illness severity before and after treatment. Pre-post random effects meta-analyses were conducted for each outcome/intervention arm studied, generating a standardised effect size (hedge's g) and 95% confidence interval (CI).
Results: A total of 34 articles describing 30 studies were included. A total of 16 separate pharmacological treatments were examined in contrast to 1 psychological therapy study. Only quetiapine and lamotrigine were assessed in >5 studies. By assessing 95% CI overlap of within-subject efficacy effects compared to placebo, the only interventions suggesting significant depression benefits (placebo g = 0.60) were olanzapine (with/without fluoxetine; g = 1.01), citalopram (g = 1.10) and venlafaxine (g = 2.48). For mania, benefits were indicated for quetiapine (g = 1.01), olanzapine (g = 1.19) and aripiprazole (g = 1.09), versus placebo (g = 0.33). Most of these effect sizes were from only one trial per treatment. Heterogeneity between studies was variable, and 20% were rated to have a high risk of bias.
Conclusions: While many interventions appeared efficacious, there was a lack of robust evidence for most treatments. Given the limited and heterogeneous evidence base, the optimal treatment strategies for people with RCBD are yet to be established.
Keywords: bipolar disorders; meta-analysis; rapid cycling; systematic review; treatment.
© 2022 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.
Conflict of interest statement
In the last 3 years: Rebecca Strawbridge declares an honorarium from Lundbeck; Allan H. Young declares honoraria for speaking from Astra Zeneca, Lundbeck, Eli Lilly, Sunovion, honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen, and research grant support from Janssen; Sameer Jauhar has received honoraria for educational talks given for Lundbeck, Sunovian and Janssen, on antipsychotics; Nefize Yalin has worked on studies conducted together with Janssen Cliag, Corcept Therapeutics and COMPASS Pathways. No other conflicts of interest are declared.
Figures


Similar articles
-
A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.Health Technol Assess. 2004 May;8(19):iii-iv, 1-187. doi: 10.3310/hta8190. Health Technol Assess. 2004. PMID: 15147609
-
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.Health Technol Assess. 2007 Oct;11(39):iii-iv, ix-206. doi: 10.3310/hta11390. Health Technol Assess. 2007. PMID: 17903393
-
Pharmacological interventions for the treatment of disordered and problem gambling.Cochrane Database Syst Rev. 2022 Sep 22;9(9):CD008936. doi: 10.1002/14651858.CD008936.pub2. Cochrane Database Syst Rev. 2022. PMID: 36130734 Free PMC article.
-
Control interventions in randomised trials among people with mental health disorders.Cochrane Database Syst Rev. 2022 Apr 4;4(4):MR000050. doi: 10.1002/14651858.MR000050.pub2. Cochrane Database Syst Rev. 2022. PMID: 35377466 Free PMC article.
-
Psychological and/or educational interventions for the prevention of depression in children and adolescents.Cochrane Database Syst Rev. 2004;(1):CD003380. doi: 10.1002/14651858.CD003380.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2011 Dec 07;(12):CD003380. doi: 10.1002/14651858.CD003380.pub3. PMID: 14974014 Updated.
Cited by
-
Acetazolamide for Bipolar Disorders: A Scoping Review.Brain Sci. 2023 Jan 13;13(1):140. doi: 10.3390/brainsci13010140. Brain Sci. 2023. PMID: 36672121 Free PMC article.
-
Collecting Contributions for a Critical Issue: Progressing from Bench to Bedside in Bipolar Disorders.Brain Sci. 2023 Aug 28;13(9):1254. doi: 10.3390/brainsci13091254. Brain Sci. 2023. PMID: 37759855 Free PMC article.
-
Sociodemographic, clinical and treatment characteristics of current rapid-cycling bipolar disorder: a multicenter Chinese study.Int J Bipolar Disord. 2024 Apr 9;12(1):11. doi: 10.1186/s40345-024-00332-z. Int J Bipolar Disord. 2024. PMID: 38592605 Free PMC article.
-
The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses.BMJ Open. 2024 Nov 5;14(11):e087999. doi: 10.1136/bmjopen-2024-087999. BMJ Open. 2024. PMID: 39500601 Free PMC article. Review.
-
Lamotrigine: A Safe and Effective Mood Stabilizer for Bipolar Disorder in Reproductive-Age Adults.Med Sci Monit. 2024 Oct 7;30:e945464. doi: 10.12659/MSM.945464. Med Sci Monit. 2024. PMID: 39370636 Free PMC article. Review.
References
-
- Diagnostic and Statistical Manual of Mental Disorders: DSM‐5. 5th ed. American Psychiatric Association; 2013. doi‐org.db29.linccweb.org/10.1176/appi.